PATIENT IDENTIFICATION
On this page:
Identifying patients 
Patient profiles 

For the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in adults

HOW ARE YOUR PATIENTS CURRENTLY MANAGING THEIR IBS-D SYMPTOMS?

  • Trying dietary and lifestyle changes

    eg, avoiding trigger foods, increasing fiber intake, avoiding stress

    • Still frequently experiencing symptoms
  • Self-treating with over-the-counter medications for occasional diarrhea

    eg, loperamide 2 mg

    • Wanting a daily treatment to help stay ahead of symptoms
  • Adding probiotic supplements to diet to help digestion

    eg, Bifidobacterium infantis

    • Wanting a treatment to help with IBS-D symptoms of abdominal pain and diarrhea

COULD VIBERZI BE THE RIGHT CHOICE FOR YOUR IBS-D PATIENTS?

Meet 2 IBS-D patients who may resemble others in your practice

Claire

28-year-old Marketing Executive
Undiagnosed; has been experiencing
symptoms for around 10 months

Not an actual patient. For illustrative purposes only.

Claire has a routine in place to help address her symptoms. She uses loperamide 2 mg when symptoms occur, but she is not satisfied and is open to trying another treatment option that proactively manages her symptoms.

“For me, the unpredictability is challenging. An episode can come on without warning.”

Symptoms: Persistent abdominal pain and loose, watery diarrhea

Abdominal pain on a scale of 0 to 10:
6
Stool consistency:
6 (mushy)

As measured by the Bristol Stool Scale.

Treatment goal: Claire wants a treatment that will help relieve her abdominal pain and diarrhea, and help her stay ahead of them.

 

William

35-year-old Teacher
Diagnosed 1 year ago

Not an actual patient. For illustrative purposes only.

William tried taking an antispasmodic 4 times a day after his last appointment 6 months ago. His abdominal pain is not as bothersome, but his diarrhea is still an issue.

“It’s frustrating. I haven’t really found anything to manage it.”

Symptoms: Mild abdominal pain and frequent diarrhea

Abdominal pain on a scale of 0 to 10:
4
Stool consistency:
6 (loose and mushy)

As measured by the Bristol Stool Scale.

Treatment goal: William wants a treatment that will help relieve both his abdominal pain and his diarrhea.

Patient Savings Program

Savings card available!

The reality of living with IBS-D

Watch Ask Me Anything.

VIBERZI patient brochure

Information about VIBERZI and IBS-D.

VIBERZI samples

Download the form to request samples.

Not eligible where prohibited by law.

Next: TARGETS RECEPTORS IN GI TRACT  

Contraindications

VIBERZI is contraindicated in patients:

Warnings and Precautions
Pancreatitis:
Sphincter of Oddi Spasm:
Hypersensitivity Reactions:
Constipation:
Adverse Reactions

The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.

Indication

VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Please also see full Prescribing Information.

 
IMPORTANT SAFETY INFORMATION
See More
Contraindications

VIBERZI is contraindicated in patients:

  • Without a gallbladder.
  • With known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; or structural diseases of the pancreas.
  • With alcoholism, alcohol abuse, alcohol addiction, or who drink more than 3 alcoholic beverages per day.
  • With a known hypersensitivity reaction to VIBERZI.
  • With severe hepatic impairment.
  • With a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Pancreatitis:
  • Pancreatitis, with or without sphincter of Oddi spasm, has been reported in patients taking either the 75 mg or 100 mg dosage of VIBERZI, including serious cases resulting in hospitalization, primarily in patients without a gallbladder. Fatal cases have also been reported in patients without a gallbladder. VIBERZI is contraindicated in patients without a gallbladder. Most of the reported cases of serious pancreatitis occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
  • In patients with a gallbladder, evaluate a patient’s alcohol intake prior to starting VIBERZI. Instruct patients to avoid chronic or acute excessive alcohol use while taking VIBERZI. Monitor for new or worsening abdominal pain that may radiate to the back or shoulder, with or without nausea and vomiting. Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of pancreatitis such as acute abdominal or epigastric pain radiating to the back or shoulder associated with elevations of pancreatic enzymes with or without nausea and vomiting.
Sphincter of Oddi Spasm:
  • There is a risk of sphincter of Oddi spasm, resulting in pancreatitis or hepatic enzyme elevation associated with acute abdominal pain (eg, biliary-type pain) in patients taking VIBERZI. Serious adverse reactions of sphincter of Oddi spasm with or without pancreatitis resulting in hospitalization have been reported, primarily in patients without a gallbladder. Cases of serious sphincter of Oddi spasm occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
  • Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain that may radiate to the back or shoulder with or without nausea and vomiting, associated with elevations of pancreatic enzymes or liver transaminases. Do not restart VIBERZI in patients who developed biliary duct obstruction while taking VIBERZI.
Hypersensitivity Reactions:
  • In postmarketing experience, serious hypersensitivity reactions (including anaphylaxis) have been reported following VIBERZI administration. Some of these reactions occurred after the first one or two doses of VIBERZI.
  • Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction.
Constipation:
  • Constipation, sometimes requiring hospitalization, has been reported following VIBERZI administration. In postmarketing experience, severe cases with development of intestinal obstruction, intestinal perforation, and fecal impaction, requiring intervention, have also been reported. Instruct patients to stop VIBERZI and immediately contact their healthcare provider if they experience severe constipation. Avoid use with other drugs that may cause constipation.
Adverse Reactions

The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.

Indication

VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Please also see full Prescribing Information.